Caputron Medical signs distribution agreement with Neurosoft

2027

Caputron Medical has entered into an agreement to distribute Neurosoft products for transcranial magnetic stimulation.

The distribution agreement gives Caputron Medical the rights to market the Neuro-MS/D Diagnostic, Therapeutic, and Advanced Therapeutic repetitive transcranial magnetic stimulation stimulators in the USA and Canada.

 

Neurosoft says that its transcranial magnetic stimulation systems combine features and performance not available in any other product, packaged in high-value systems for customers. These unique performance features include a high-performance cooling system capable of performing up to 10,000 pulses during one session, a peak magnetic field of up to 4 Tesla and20 Hz stimulation with 100% intensity. Neurosoft products are used internationally at leading medical research centres in the study of the non-invasive neuromodulation with applications areas in psychiatry, neurology, cognitive neuroscience, clinical neurophysiology and rehabilitation.

Robin Azzam, chief executive officer of Caputron Medical, commented: “These products will complement our transcranial direct current stimulation (tDCS) and High Definition-tDCS systems provided through Soterix Medical and our broad range of neuromodulation accessories. Caputron Medical is a proud provider of ANT Neuro EEG and neuronavigation systems that pair seamlessly with Neurosoft products.”

Michael Durdin, chief of development, said, “Customers are becoming more educated and have higher expectations for transcranial magnetic stimulation products—they will no longer accept having to buy multiple systems, coils, or accessories for each application. Neurosoft systems are a ‘one-stop’ solution mirroring the broader commitment of Caputron Medical to be a ‘one-stop’ source in advanced brain research and modulation.”